Treatment of advanced gastric cancer with oxaliplatin plus 5-fluorouracil/ leucovorin (FOLFOX-4 chemotherapy)

Chemotherapy improves survival in advanced gastric cancer. However the most active combinations have a high level of toxicity that limits their use. To assess the response, toxicity and survival of patients with advanced gastric cancer, treated with oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX...

Full description

Saved in:
Bibliographic Details
Published in:Revista medíca de Chile 2007-11, Vol.135 (11), p.1380
Main Authors: Garrido, Marcelo, Melgoza, Geraldine, Galindo, Héctor, Madrid, Jorge, Sánchez, César, Nervi, Bruno, Alvarez, Manuel, Orellana, Eric
Format: Article
Language:Spanish
Subjects:
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Female
Fluorouracil - administration & dosage
Fluorouracil - adverse effects
Humans
Leucovorin - administration & dosage
Leucovorin - adverse effects
Male
Middle Aged
Neoplasm Staging
Organoplatinum Compounds - administration & dosage
Organoplatinum Compounds - adverse effects
Pyridines - administration & dosage
Pyridines - adverse effects
Stomach Neoplasms - drug therapy
Stomach Neoplasms - mortality
Survival Analysis
Treatment Outcome
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chemotherapy improves survival in advanced gastric cancer. However the most active combinations have a high level of toxicity that limits their use. To assess the response, toxicity and survival of patients with advanced gastric cancer, treated with oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4 chemotherapy). Patients with stage IV gastric cancer, according to the American Joint Committee on Cancer or with relapsed disease and functional capacity 0-2 of the South West Oncology Group, were included. FOLFOX-4 chemotherapy was used as first or second line treatment. The response to treatment and survival were assessed. Between 2003 and 2006, 29 patients (median age 52.5 years, 69% males) were treated. FOLFOX-4 was given as first line treatment in 65% patients and as second line in 35%. There was a complete response in 4.6%, partial response in 68%, stable disease in 20.6% and progression in 6.8%. Toxicity was observed in 51% of patients, that was hematological and non hematological grade 3/4 in 14%. Median survival was 12.5 months. FOLFOX-4 chemotherapy was active in advanced gastric cancer and had a low level of toxicity.
ISSN:0034-9887